UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 11.

Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, J; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, M; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; Moos, R von; Zaman, K; Goldhirsch, A; Swiss Group for Clinical Cancer Research (SAKK) (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Annals of Oncology, 28(2):305-312.

Joerger, M; Thürlimann, B; Savidan, A; Frick, H; Rageth, C; Lütolf, U; Vlastos, G; Bouchardy, C; Konzelmann, I; Bordoni, A; Probst-Hensch, N; Jundt, G; Ess, S (2013). Treatment of breast cancer in the elderly: A prospective, population-based Swiss study. Journal of Geriatric Oncology, 4(1):39-47.

Chirgwin, J; Sun, Z; Smith, I; Price, K N; Thürlimann, B; Ejlertsen, B; Bonnefoi, H; Regan, M M; Goldhirsch, A; Coates, A S (2012). The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Research and Treatment, 131(1):295-306.

Regan, M M; Neven, P; Giobbie-Hurder, A; Goldhirsch, A; Ejlertsen, B; Mauriac, L; Forbes, J F; Smith, I; Láng, I; Wardley, A; Rabaglio, M; Price, K N; Gelber, R D; Coates, A S; Thürlimann, B (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncology, 12(12):1101-1108.

Regan, M M; Price, K N; Giobbie-Hurder, A; Thürlimann, B; Gelber, R D (2011). Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Research, 13(3):209.

Ess, S; Joerger, M; Frick, H; Probst-Hensch, N; Vlastos, G; Rageth, C; Lütolf, U; Savidan, A; Thürlimann, B (2011). Predictors of state-of-the-art management of early breast cancer in Switzerland. Annals of Oncology, 22(3):618-624.

Ess, S; Savidan, A; Frick, H; Rageth, C H; Vlastos, G; Lütolf, U; Thürlimann, B (2010). Geographic variation in breast cancer care in Switzerland. Cancer Epidemiology, 34(2):116-121.

Rochlitz, C; Senn, H-J; Betticher, D; Helbling, D; von Moos, R; Pestalozzi, B; Thürlimann, B; Uebelhart, D; Aapro, M (2010). Der Einsatz von Bisphosphonaten bei der Behandlung solider Tumoren. Swiss Medical Forum, 10(34):562-564.

Pagani, O; Gelber, S; Simoncini, E; Castiglione-Gertsch, M; Price, K N; Gelber, R D; Holmberg, S B; Crivellari, D; Collins, J; Lindtner, J; Thürlimann, B; Fey, M F; Murray, E; Forbes, J F; Coates, A S; Goldhirsch, A (2009). Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Research and Treatment, 116(3):491-500.

Rabaglio, M; Sun, Z; Price, K N; Castiglione-Gertsch, M; Hawle, H; Thürlimann, B; Mouridsen, H; Campone, M; Forbes, J F; Paridaens, R J; Colleoni, M; Pienkowski, T; Nogaret, J M; Láng, I; Smith, I; Gelber, R D; Goldhirsch, A; Coates, A S (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of Oncology, 20(9):1489-1498.

Mouridsen, H; Giobbie-Hurder, A; Goldhirsch, A; Thürlimann, B; Paridaens, R; Smith, I; Mauriac, L; Forbes, J F; Price, K N; Regan, M M; Gelber, R D; Coates, A S (2009). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New England Journal of Medicine, 361(8):766-776.

This list was generated on Fri Jul 21 09:22:42 2017 CEST.